For informational purposes only — not investment advice

← Back to signals

HUM

LONGCONGRESS BUY

HUMANA INC

Research: Finviz ↗·Perplexity ↗

🗄 Viewing archived Q1 2026 data — frozen, no longer refreshed.

Funds
3
Score
3.25
vs SPY
+105.2%
Stock return (since Q-end)
+124.9%
SPY return (since Q-end)
+19.7%
Current price
$389.05
Days to cover (short int.)
2.5d
as of 2026-06-30

News Summary

Negative

Humana reported Q2 earnings beats with medical costs tracking expectations, but significantly cut full-year 2026 GAAP EPS guidance to $6.52 (from $8.36) due to a severe 'star ratings cliff' creating a $3.5B revenue headwind—membership in 4+ star plans collapsed from 94% to 45% due to stricter federal scoring. While CMS approved a strong 2.48% 2027 MA rate increase and the company won new Medicaid contracts, the near-term profitability headwinds, failed star ratings appeal, and planned MA exits affecting 600k members represent substantial near-term challenges.

Red flags

  • •GAAP EPS guidance slashed 22% to $6.52 from initial $8.36 full-year outlook
  • •Star ratings cliff: 94% of members in 4+ star plans (2024) fell to ~45% (2026), creating $3.5B net revenue headwind
  • •CMS appeal for star ratings improvement denied in April 2026
  • •Planned exits of approximately 600k members from Medicare Advantage plans with low star ratings
  • •2026 Adjusted EPS guidance expects year-over-year decline vs. 2025
  • •Analyst disappointment with maintained (not raised) 2026 guidance despite Q2 beat, contrasting with peer performance

Funds Buying (3)

FundManagerShares Held∆ SharesPosition Value% of FundQoQStatus
Glenview CapitalLarry Robbins335K+335K$58M1.6%—NEW
Duquesne Family OfficeStanley Druckenmiller138K+138K$24M0.8%—NEW
Soros Fund ManagementSoros Family Office68K+17K$12M0.2%+34%Existing

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.

Portfolio Context

Where HUM ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.

Glenview Capital

position #19 of this fund's book

  1. 16APPLIED MATLS INC$67M
  2. 17ONTO INNOVATION INC$61M
  3. 18DICKS SPORTING GOODS INC$59M
  4. 19HUMANA INC$58M
  5. 20BUTTERFLY NETWORK INC$58M
  6. 21ELEMENT SOLUTIONS INC$56M
  7. 22UNITED AIRLS HLDGS INC$46M
Duquesne Family Office

position #26 of this fund's book

  1. 23Lattice Semiconductor Corp$30M
  2. 24Sandisk Corp$24M
  3. 25United Airls Hldgs Inc$24M
  4. 26Humana Inc$24M
  5. 27Wabtec$24M
  6. 28Twilio Inc$23M
  7. 29Jabil Inc$22M

Values are quarter-end position sizes. Shown only for funds where HUM ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.

Signal History

QuarterDirectionFundsScorevs SPY
Q3 2026LONG44.20+5.9%
Q1 2026LONG33.25+105.2%

Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.

Congressional Trading

MemberChamberStateTypeAmount RangeTransaction DateFiledSrc
Alan Armstrongsenate—BUY$1,001 - $15,0002026-03-272026-07-21↗

Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures. Members often file weeks or months after trading, so trades are placed by transaction date: the badges above count trades dated since Jan 1, 2026.